Search research articles
Contact Us
Filters
Showing results (1-10 of 526) with videos related to
Page
of 53
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1993
Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee
M Marty
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1990
A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group
M Marty
Pathologie-Biologie
|
May 9, 2008
[An emerging bridge between supportive and specific care]
M Marty
Bulletin Du Cancer
|
December 1, 1996
[Chemotherapy-induced nausea and vomiting: from experimentation to experience]
M Marty
Oncology
|
May 1, 1993
Future trends in cancer treatment and emesis control
M Marty
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review
M Marty
JDR Clinical and Translational Research
|
April 2, 2019
Time Loss
M Marty
European Journal of Cancer & Clinical Oncology
|
January 1, 1989
Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting
M Marty
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
|
February 27, 1999
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of Quality Assurance General Regime]
M Marty
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group
M Marty
Page
of 53
Search research articles
Search
Showing results (1-10 of 526) with videos related to
Sort By:
Page
of 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1993
Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee
M Marty
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1990
A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group
M Marty
Pathologie-Biologie
|
May 9, 2008
[An emerging bridge between supportive and specific care]
M Marty
Bulletin Du Cancer
|
December 1, 1996
[Chemotherapy-induced nausea and vomiting: from experimentation to experience]
M Marty
Oncology
|
May 1, 1993
Future trends in cancer treatment and emesis control
M Marty
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review
M Marty
JDR Clinical and Translational Research
|
April 2, 2019
Time Loss
M Marty
European Journal of Cancer & Clinical Oncology
|
January 1, 1989
Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting
M Marty
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
|
February 27, 1999
[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of Quality Assurance General Regime]
M Marty
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group
M Marty
Page
of 53